Merck Healthcare in the news

Merck acquired global rights to SciBrunch Therapeutics' experimental cancer drug, SPR2015, for up to $2.13 billion to target the KRAS G12D mutation in various cancers.

Merck's oral cholesterol candidate achieved its primary and key secondary goals in a pivotal study, marking a significant step in its cardiovascular pipeline and offering a potential oral alternative to injectable treatments.

Merck secured FDA approval for Welireg in advanced renal cell carcinoma, licensed an oral KRAS inhibitor, and withdrew a lung cancer drug application.

Merck & Co. achieved multiple regulatory milestones in oncology, including a Japanese clearance for a subcutaneous formulation and a positive European opinion for a bladder cancer regimen, during a period of market caution.

Merck is focusing on new drug development and acquisitions to prepare for Keytruda's patent expiration, navigating market shifts and healthcare policy changes.

Merck's stock is under scrutiny for its pharmaceutical pipeline execution during a critical healthcare week, amidst a selective market influenced by interest rates and energy prices.

Merck's current market position is heavily influenced by its pharmaceutical pipeline execution amidst a week packed with healthcare news and broader economic factors.

Merck Healthcare Korea launched a campaign to raise awareness about children's growth monitoring and introduced its Growzen Ecosystem for data-driven growth hormone treatment.

Merck strengthens its presence in China by launching a rare disease awareness campaign focusing on desmoid tumors.

Merck strengthens its commitment to China by investing in innovation and rare disease awareness, particularly through an exhibition focused on desmoid tumors.

Merck Healthcare Vietnam inaugurated a new office in Ho Chi Minh City, emphasizing employee well-being and a supportive work environment.

Merck Healthcare Korea partnered with the Korean Society for Reproductive Medicine to develop educational content for infertility patients.

Merck outlined an ambitious pipeline and commercial strategy at the Morgan Stanley healthcare conference, highlighting advancements in oncology, cardiovascular, and immunology programs, and expressing confidence in exceeding its $70 billion mid-2030s revenue target.

Merck Healthcare Korea and the Korean Society of Reproductive Medicine partnered to provide educational resources for infertility patients.

Kenya is exploring collaboration with Merck Healthcare and Life Science to boost its health sector through biotechnology, local pharmaceutical manufacturing, and capacity building.

Merck's growth depends on expanding its cancer and other treatment pipelines to overcome valuation concerns, pricing pressures, and patent expirations.

The Merck Foundation is contributing $2 million to the UN Foundation's Outbreak Prevention and Preparedness Fund to boost immunization efforts and combat vaccine-preventable diseases in low- and middle-income countries.

The Merck Foundation supported HIV Care Connect, a program focused on improving HIV care access and outcomes for people of color in the Southeastern U.S. through a $7 million commitment.

Merck Foundation funds programs in South Africa to improve HIV care for men who have sex with men through partnerships with mothers2mothers and Population Services International.

Merck Healthcare Vietnam opened a new 700m² office in the German House to support healthcare initiatives and foster collaboration.